Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
AbbVie is a drug company that invents and sells medicines, mostly for immune diseases, cancer, and other serious conditions.
AbbVie is a giant drugmaker, the kind of company that spends years and billions of dollars turning molecules into medicines, then sells those medicines to hospitals, doctors, and patients around the world. Its biggest and most famous product is Humira, an injection that tames an overactive immune system and has been used by millions of people with arthritis, Crohn's disease, and psoriasis. Humira was once the best-selling medicine on earth, and for years it was the engine that drove almost everything at AbbVie. Then its patents expired, cheaper copies arrived in the United States in 2023, and the drug's sales fell sharply. That was the central drama of the company's recent history: what happens when the goose that laid the golden eggs suddenly stops.
AbbVie's answer was to build new geese. It has two newer immune-disease drugs, Skyrizi and Rinvoq, that are now growing fast enough to replace Humira's lost sales, and the company has said those two together should eventually top what Humira ever made. Cancer is the other big pillar. Imbruvica treats certain blood cancers, and AbbVie also sells a large basket of cancer drugs through its oncology business. On top of that, it makes Botox, the famous wrinkle smoother that also happens to treat migraines and muscle spasms. AbbVie picked up Botox when it bought Allergan for about $63 billion in 2020, a deal that also added eye-care and other treatments and widened the company's base beyond its heavy reliance on immune drugs. The customers are not really the people swallowing the pills — it is insurers and government health programs that pay the bills, and they push back hard on price. What makes AbbVie strong is also what makes it risky. New drugs are protected by patents for a stretch of years, which lets the company charge high prices and earn fat profits. But when those patents run out, generics and copycat "biosimilars" flood in and prices collapse. That is what happened with Humira, and it will eventually happen to today's stars too. So AbbVie must constantly invent or buy the next wave of medicines before the old ones fade. The company spends heavily on research and development and makes big acquisitions to refill the pipeline — Allergan was the largest, but there have been others, including a deal for Cerevel Therapeutics to add brain-disease drugs. Its biggest competitors are other major drugmakers such as Johnson & Johnson, Pfizer, Merck, and Amgen, all chasing the same diseases and the same insurance dollars.
Abbott Laboratories was a big health company with two very different halves: one made medical devices, the other made prescription drugs. In 2013 it split them into two public companies, and the drug half became AbbVie. The problem was that AbbVie's drug business leaned on one medicine, Humira, for about half its revenue, and Humira's patents were running out. Some investors even suspected the split was a way to protect the steadier device business from the pain coming to the drug unit.
AbbVie then tried to buy the drugmaker Shire. It was a huge deal, and part of the appeal was a tax trick: moving the company's legal home to Ireland to pay less tax, called an inversion. But the US Treasury changed the tax rules mid-deal, and the plan fell apart. AbbVie walked away paying a $1.6 billion breakup fee for the trouble.
Instead of Shire, AbbVie went shopping for cancer drugs. It won a bidding fight against AstraZeneca for Pharmacyclics, the company behind a blood-cancer drug called ibrutinib. The price was about $21 billion, but it handed AbbVie a real cancer business — its first serious step away from depending on Humira.
A few years later AbbVie made its biggest bet yet: about $63 billion for Allergan, the company known for Botox. This one was structured so AbbVie stayed legally American for tax purposes, and to get regulators to approve it, AbbVie sold off a few Allergan drugs. The point was to add beauty treatments and brain-and-nerve medicines before Humira's sales started to fall.
Then the day AbbVie had feared finally came. In early 2023, copycat versions of Humira, called biosimilars, began selling. Humira had been the best-selling drug in the world and the engine of AbbVie's revenue since the spinoff, so this was the long-dreaded patent cliff — the moment the cash machine starts slowing down.
With Humira money shrinking, AbbVie spent 2024 buying new engines. It completed the purchase of ImmunoGen, which brought a technology that delivers cancer drugs directly to tumors, and later closed the deal for Cerevel Therapeutics to add brain and nerve medicines. Both were about stocking the pipeline for a future without Humira.
That same year, on July 1, Robert A. Michael stepped up from president and COO to CEO, replacing Richard A. Gonzalez, who had run the company since the 2013 spinoff and became executive chairman. The handoff came right in the middle of managing the Humira cliff and rebuilding for growth.
AbbVie kept buying. In 2025 it agreed to pay more than $10.9 billion for Apogee Therapeutics, whose main asset was an antibody for eczema and other inflammatory diseases. This was a bet on staying king of immunology as AbbVie built successors to its hit drugs Skyrizi and Rinvoq.
By the third quarter of 2026, the turnaround showed up in the numbers. Revenue rose more than 10% to $17.4 billion, with Skyrizi and Rinvoq driving strong immunology growth and neuroscience rising fast. AbbVie raised its full-year guidance and hiked its dividend — proof it had climbed out of the Humira cliff with new growth engines in place.
The money machine here is remarkable. AbbVie generates billions in free cash flow, and it hands a big chunk back to shareholders through a dividend that has risen every year since the company was spun off from Abbott Laboratories in 2013. It also buys back stock. The honest picture: this is a highly profitable business built on patent-protected medicines, but it lives with the constant threat that its best products will one day lose their protection, and its future depends on whether the next batch of drugs arrives in time. So far, Skyrizi and Rinvoq are doing exactly what the company hoped.
Saved answer · last researched 31 Oct 2026